Stakeholders in Clinical Trials Market Harness Internet of Medical Things (IoMT) to Explore New Frontiers in Vaccine Development: TMR
-
Clinical trial management groups harness virtual trial tools to boost recruitment, paving way to innovations
ALBANY, N.Y., Feb. 11, 2021 /PRNewswire/ Clinical trials community, including industry and the academia, has been relentlessly conducting studies to mitigate and prevent outbreaks of infectious diseases. Ongoing trials around the world underpin hopes of new drugs and therapies. The recent one, COVID-19 pandemic, has brought forth several unique challenges for the trial managers, upending the whole trial processes. Unprecedentedly, the COVID-19 has caused community-wide disruptions, pressing for urgent need for speeding up the current trials in various nations. In the backdrop of these trends, the clinical trials market is poised to witness new avenues over new few months. Unique set of challenges faced by trial managers include low rec
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
LONDON, Feb. 11, 2021 /PRNewswire/ BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. This significant milestone sees a best in class, novel multi-target drug developed using BenevolentAI s scientific and technical expertise now entering human clinical trials.
BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. In this initial trial, BEN-2293 will be studied in adult patients with mild to moderate disease.
California is making liberals squirm
Ezra Klein, New York Times
Feb. 11, 2021
FacebookTwitterEmail
FILE: An aerial view of San Francisco on a sunny day.Ivan/Getty Images
You may have heard that San Francisco’s Board of Education voted 6-1 to rename 44 schools, stripping ancient racists of their laurels, but also Abraham Lincoln and Sen. Dianne Feinstein. The history upon which these decisions were made was dodgy, and the results occasionally bizarre. Paul Revere, for instance, was canceled for participating in a raid on Indigenous Americans that was actually a raid on a British fort.
In normal times, bemusement would be the right response to a story like this. Cities should have idiosyncratic, out-there politics. You need to earn your “Keep X weird” bumper stickers. And for all the Fox News hosts who’ve collapsed onto their fainting couches, America isn’t suffering from a national shortage of schools named for Abraham Lincoln.
Former Leader of the Centers of Medicare & Medicaid Services (CMS) Joins ProgenyHealth Board yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.